These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25622891)

  • 1. Characteristic molecular vibrations of adenosine receptor ligands.
    Chee HK; Yang JS; Joung JG; Zhang BT; Oh SJ
    FEBS Lett; 2015 Feb; 589(4):548-52. PubMed ID: 25622891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
    Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
    Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
    Ciancetta A; Cuzzolin A; Moro S
    J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
    Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
    Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent ligands for adenosine receptors.
    Kozma E; Jayasekara PS; Squarcialupi L; Paoletta S; Moro S; Federico S; Spalluto G; Jacobson KA
    Bioorg Med Chem Lett; 2013 Jan; 23(1):26-36. PubMed ID: 23200243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal chemistry of adenosine, P2Y and P2X receptors.
    Jacobson KA; Müller CE
    Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Updates in the Computer Aided Drug Design Strategies for the Discovery of Agonists and Antagonists of Adenosine Receptors.
    Deb PK
    Curr Pharm Des; 2019; 25(7):747-749. PubMed ID: 31232230
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicinal chemistry of adenosine A1 receptor ligands.
    Soudijn W; van Wijngaarden I; IJzerman AP
    Curr Top Med Chem; 2003; 3(4):355-67. PubMed ID: 12570755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).
    Jacobson KA
    Bioconjug Chem; 2009 Oct; 20(10):1816-35. PubMed ID: 19405524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine receptor desensitization and trafficking.
    Mundell S; Kelly E
    Biochim Biophys Acta; 2011 May; 1808(5):1319-28. PubMed ID: 20550943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
    Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
    PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways.
    Agarwal R; Agarwal P
    Expert Opin Ther Targets; 2014 May; 18(5):527-39. PubMed ID: 24579961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical structure-activity studies of adenosine A1 ligands: requirements for receptor affinity.
    Dooley MJ; Kono M; Suzuki F
    Bioorg Med Chem; 1996 Jun; 4(6):923-34. PubMed ID: 8818243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.
    Tintori C; Manetti F; Botta M
    Curr Top Med Chem; 2010; 10(10):1019-35. PubMed ID: 20370655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling the human A1 adenosine receptor and study of the mechanisms of its selective ligand binding.
    Ivanov AA; Baskin II; Palyulin VA; Zefirov NS
    Dokl Biochem Biophys; 2002; 386():271-4. PubMed ID: 12469507
    [No Abstract]   [Full Text] [Related]  

  • 16. Adenosine A2A receptor agonists: CoMFA-based selection of the most predictive conformation.
    Doytchinova I; Valkova I; Natcheva R
    SAR QSAR Environ Res; 2002 Mar; 13(2):227-35. PubMed ID: 12071651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomenclature and classification of purinoceptors.
    Fredholm BB; Abbracchio MP; Burnstock G; Daly JW; Harden TK; Jacobson KA; Leff P; Williams M
    Pharmacol Rev; 1994 Jun; 46(2):143-56. PubMed ID: 7938164
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of Fluorescent Purinoceptor Antagonists for Bioluminescence Resonance Energy Transfer Assays and Fluorescent Microscopy.
    Soave M; Goulding J; Markus R; Hill SJ; Stoddart LA
    Methods Mol Biol; 2020; 2041():163-181. PubMed ID: 31646488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-objective evolutionary design of adenosine receptor ligands.
    van der Horst E; Marqués-Gallego P; Mulder-Krieger T; van Veldhoven J; Kruisselbrink J; Aleman A; Emmerich MT; Brussee J; Bender A; Ijzerman AP
    J Chem Inf Model; 2012 Jul; 52(7):1713-21. PubMed ID: 22647079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.
    Kudlacek O; Just H; Korkhov VM; Vartian N; Klinger M; Pankevych H; Yang Q; Nanoff C; Freissmuth M; Boehm S
    Neuropsychopharmacology; 2003 Jul; 28(7):1317-27. PubMed ID: 12784121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.